drugset / Trial / NCT00582166
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
NaSingle-groupOpen-labelTreatment
Summary
Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
Timeline
- Start
- 2005-01-25
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Outcome not reported
Stopped: “See 'Limitations and Caveats' section”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | — | — |